Recombinant Listeria monocytogenes cancer vaccines

Current Opinion in Immunology

Volumn 8, Issue 5, 1996, Pages 664-669

  Paterson, Yvonne ^a   Ikonomidis, Georgios ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Hellenic Anti cancer Institute   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; TUMOR ANTIGEN;

CANCER IMMUNOTHERAPY; COMBINED IMMUNODEFICIENCY; HUMAN; IMMUNE SYSTEM; LISTERIA MONOCYTOGENES; REVIEW; T LYMPHOCYTE;

EID: 0030272694     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(96)80083-5     Document Type: Article

References (48)

1. Boon T, Cerottini J-C, Van den Eynde B, Van den Bruggen P. Tumour antigens recognized by T lymphocytes. Annu Rev Immunol. 12:1994;337-365.
2. Pardoll DM. Cancer Vaccines. Trends Pharmacol Sci. 14:1993;202-208.
3. Pardoll DM. A new look for the 1990s. Nature. 369:1994;357-358.
4. Schafer R, Portnoy DA, Brassell SA, Paterson Y. Induction of a cellular immune response to a foreign antigen by a recombinant Listeria monocytogenes vaccine. J Immunol. 149:1992;53-59.
5. Ikonomidis G, Paterson Y, Kos F, Portnoy D. Delivery of a viral antigen to the class I processing and presentation pathway by L. monocytogenes. J Exp Med. 180:1994;2209-2218.
6. of special interest Shen H, Slifka MK, Matloubian M, Jensen ER, Ahmed R, Miller JF. Recombinant Listeria monocytogenes as a live vaccine vehicle for the induction of protective anti-viral cell-mediated immunity. Proc Natl Acad Sci USA. 92:1995;3987-3991 Clearly demonstrates the ability of a stable L. monocytogens recombinant strain to induce immunity to a viral antigen that is potent enought to protect against infection in vivo.
7. + T cells in vivo: a study with the nucleoprotein of the lymphocytic chriomeningitis virus. Int Immunol. 7:1995;797-805.
8. of outstanding interest Pan Z-K, Ikonomidis G, Lazenby A, Pardoll D, Paterson Y. A recombinant Listeria monocytogenes vaccine expressing a model tumor antigen protects mice against lethal tumor challenge and causes regression of established tumors. Nat Med. 1:1995;471-477 Using a model system of colon and rectal carcinomas that express influenza NP and the recombinant L. monocytogenes described in reference [5], it was shown that this organism could induce the regression of established macroscopic tumors, thus demonstrating its potential as a cancer therapeutic.
9. of special interest Pan Z-K, Ikonomidis G, Pardoll D, Parterson Y. Regression of established tumors in mice mediated by the oral administration of a recombinant Listeria monocytogenes vaccine. Cancer Res. 55:1995;4776-4779 Infection by L. monocytogenes is normally through the gut, which opens up the exciting possibility of the use of this organism as an oral cancer vaccine. Here it was shown, using the same model system described in [8], that oral admisistration was, indeed, an effective vaccine route.
10. of special interest Frankel FR, Hegde S, Lieberman J, Paterson Y. Induction of cell-mediated immune responses to human immunodeficiency virus type 1 Gag protein by using Listeria monocytogenes as a live vaccine vector. J Immunol. 155:1995;4775-4782.
11. Kaufmann SHE. Immunity to intracellular bacteria. Annu Rev Immunol. 11:1993;129-163.
12. Falkow S, sIsberg RR, Portnoy DA. The interaction of bacteria with mammalian cells. Annu Rev Cell Biol. 8:1992;333-363.
13. Tilney LG, Portnoy DA. Actin filaments and the growth, movement and spread of the intracellular bacterial parasite Listeria monocytogenes. J Cell Biol. 109:1989;1597-1608.
14. Portnoy DA, Schreiber RD, Connelly P, Tilney LG. Gamma interferon limits access of Listeria monocytogenes to the macrophage cytoplasm. J Exp Med. 170:1989;2141-2146.
15. + Listeria immune T cells. Immunology. 60:1987;287-293.
16. + cells in acquired immunity. Infect Immun. 56:1988;1920-1925.
17. + T cells requires secretion of hemolysin and intracellular bacterial growth. J Immunol. 145:1990;3540-3546.
18. Berche P, Gaillard J, Sansonetti PJ. Intracellular growth of Listeria monocytogenes as a prerequisite for in vivo induction of T cell-mediated immunity. J Immunol. 138:1987;2266-2271.
19. Newborg MF, North RJ. ON the mechanism of T cell independent anti-Listeria resistance in nude mice. J Immunol. 124:1980;571-576.
20. Portnoy DA. Innate immunity to a facultative intracellular bacterial pathogen. Curr Opin Immunol. 4:1992;20-24.
21. 2-microglobulin-deficient mice. Infect Immun. 61:1993;1113-1116.
22. + T cells specific for a single nonamer epitope of Listeria monocytogenes are protective in vivo. J Exp Med. 175:1992;1531-1538.
23. + T cells are largely induced by proteins secreted by the bacteria.
24. + T lymphocytes with protective and chemotactic activities in vivo. Infect Immun. 59:1991;4531-4539.
25. Harty JT, Schreiber RD, Bevan MJ. CD8 T cells can protect against an intracellular bacterium in an interferon-gg independent fashion. Proc Natl Acad Sci USA. 89:1992;11612-11616.
26. + T cells through IL-12 produced by Listeria-induced macrophages. Sciences. 260:1993;547-549.
27. Daugelat S, Ladel CH, Schoel B, Kaufmann SHE. Antigen-specific T cell responses during primary and secondary L. monocytogenes infection. Infect Immun. 62:1994;1881-1888.
28. Scott P, Kaufmann SHE. The role of T-cell subsets and cytokines in the regulation of infection. Immunol Today. 12:1991;346-348.
29. Samson JN, Langermans JA, Savelkouf HF, Van Furth R. Tumor necrosis factor, but not interferon-gamma, is essential for acquired resistance to Listeria monocytogenes during a secondary infection in mice. Immunology. 86:1995;256-262.
30. Tripp CS, Kanagawa O, Unanue ER. Secondary response of Listeria infection requires IFN-γ but is partially independent of IL-12. J Immunol. 155:1995;3427-3432.
31. Mielke MEA, Ehlers S, Hahn H. The role of cytokines in experimental listeriosis. Immunobiology. 189:1993;285-315.
32. Ehlers S, Mielke MEA, Blankenstein T, Hahn H. Kinetic analysis of cytokine gene expression in the livers of naive and immune mice infected with L. monocytogenes. J Immunol. 149:1992;3016-3022.
33. Tripp CS, Wolf SF, Unanue ER. Interleukin 12 and tumor necrosis factor-α are costimulators of interferon-γ production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist. Proc Natl Acad Sci USA. 90:1993;3725-3729.
34. Harty JT, Bevan MJ. Specific immunity to Listeria monocytogenes in the absence of IFN-γ Immunity. 3:1995;103-117.
35. Huang S, Hendriks W, Althage A, Hemmi S, Bluethmann H, Kamijo R, Vilcek J, Zinkernagel RM, Aguet M. Immune responses in mice that lack the interferon-γ receptor. Science. 259:1993;1742-1745.
36. Havell EA. Evidence that tumor necrosis factor has an important role in antibacterial resistance. J Immunol. 143:1989;2894-2899.
37. Rothe J, Lesslauer W, Lotscher H, Lang Y, Koebel P, Kontgen F, Althage A, Zinkernagel R, Steinmetz N, Bluethmann H. Mice lacking the tumor necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature. 364:1993;798-802.
38. Pfeffer K, Matsuyama T, Kundig TM, Wakeham A, Kishihara K, Shahinian A, Wiegmann K, Ohashi PS, Kronke M, Mak TW. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock yet succumb to L. monocytogenes infection. Cell. 73:1993;457-467.
39. Rogers HW, Sheehan KCF, Brunt M, Dower SK, Unanue ER, Schreiber RD. Interleukin 1 participates in the developement of anti-Listeria responses in normal and SCID mice. Proc Natl Acad Sci USA. 89:1992;1011-1015.
40. Tripp CS, Gately MK, Hakimi J, Ling P, Unanue ER. Neutralization of IL-12 decreases resistance to Listeria in SCID and CB-17 mice. J Immunol. 152:1994;1883-1887.
41. Lassam N, Jay G. Suppression of MHC class I RNA in highly oncogenic cells occurs at the level of transcription initiation. J Immunol. 143:1989;3792-3797.
42. Doyle A, Martin WJ, Funa K, Gazdar D, Carney SE, Martin I, Linnoila F, Cuttita F, Mulshine J, Bunn P, Minna J. Markedly decreased expression of class I histocompatibility antigens protein and mRNA on human small-cell lung cancer. J Exp Med. 161:1985;1135-1151.
43. Restifo NP. Identification of human cancers deficient in antigen processing. J Exp Med. 177:1993;265-272.
44. Asher Al, Mule JJ, Kasid A, Restifo NP, Salo JC, Reichert CM, Jaffe G, Fendley B, Kriegler M, Rosenberg SA. Murine tumor cells transduced with the gene for tumor necrosis factor-α J Immunol. 146:1991;3227-3234.
45. Blankenstein T, Qin Z, Ueberla K, Mueller W, Rosen H, Volk HD, Diamantstein T. Tumor suppression after tumor cell-targeted tumor necrosis factor gene transfer. J Exp Med. 173:1991;1042-1052.
46. Porgador A, Tzehova E, Katz A, Vadai E, Revel M, Feldman M, Eisenbach L. Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res. 52:1992;3679-3686.
47. Baskar S, Ostrand-Rosenberg S, Nabavi N, Nadler LM, Freeman GJ, Glimcher LH. Consititutive expression of B7 restores the immunogenicity of tumor cells expressing truncated MHC class II molecules. Proc Natl Acad Sci USA. 90:1993;5687-5690.
48. Guo Y, Wu M, Chen H, Wang X, Liu G, Li G, Ma J, Sy M-S. Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. Science. 263:1994;518-520.